Portal hypertension is associated with increased mRNA levels of vasopressor G-protein-coupled receptors in human hepatic arteries

European Journal of Clinical Investigation

Volumn 33, Issue 3, 2003, Pages 249-255

  Neef, Markus ^a   Biecker, E ^b   Heller, J ^a   Schepke, M ^a   Nischalke, H D ^a   Wolff, M ^a   Spengler, U ^a   Reichen, J ^b   Sauerbruch, T ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

G protein coupled receptors; MRNA levels; Portal hypertension; Vascular hyporeactivity

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ARGIPRESSIN RECEPTOR; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; G PROTEIN COUPLED RECEPTOR; HYPERTENSIVE FACTOR; MESSENGER RNA; RECEPTOR SUBTYPE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATIC ARTERY; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; STEADY STATE; VASCULAR SMOOTH MUSCLE;

ADULT; FEMALE; HEPATIC ARTERY; HUMANS; HYPERTENSION, PORTAL; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, ANGIOTENSIN; RECEPTORS, CELL SURFACE; RECEPTORS, ENDOTHELIN; RECEPTORS, VASOPRESSIN; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 12444332012     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01131.x     Document Type: Article

References (38)

1. Murray JF, Dawson AM, Sherlock S. Circulatory changes in chronic liver disease. 1958;24:358-67.
2. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994;20 (5):1359-63.
3. Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. Hepatology 1990;11 (6):1066-78.
4. MacGilchrist AJ, Sumner D, Reid JL. Impaired pressor reactivity in cirrhosis: evidence for a peripheral vascular defect. Hepatology 1991;13 (4):689-94.
5. Nicholls KM, Shapiro MD, Van Putten VJ, Kluge R, Chung HM, Bichet DG et al. Elevated plasma norepinephrine concentrations in decompensated cirrhosis. Association with increased secretion rates, normal clearance rates, and suppressibility by central blood Volume expansion. Circ Res 1985;56 (3):457-61.
6. Lunzer MR, Newman SP, Bernard AG, Manghani KK, Sherlock SP, Ginsburg J. Impaired cardiovascular responsiveness in liver disease. Lancet 1975;2 (7931):382-5.
7. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest 1965;44:1171-86.
8. Willett I, Esler M, Burke F, Leonard P, Dudley F. Total and renal sympathetic nervous system activity in alcoholic cirrhosis. J Hepatol 1985;1 (6):639-48.
9. Akriviadis EA, Ervin MG, Cominelli F, Fisher DA, Reynolds TB. Hyponatremia of cirrhosis: role of vasopressin and decreased 'effective' plasma. Volume Scand J Gastroenterol 1997;32 (8):829-34.
10. Trevisani F, Colantoni A, Gerbes AL, Gulberg V, Sica G, Caraceni P et al. Daily profile of plasma endothelin-1 and -3 in pre-ascitic cirrhosis: relationships with the arterial pressure and renal function. J Hepatol 1997;26 (4):808-15.
11. Heller J, Schepke M, Gehnen N, Molderings GJ, Muller A, Erhard J et al. Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology 1999;116 (2):387-93.
12. Schepke M, Heller J, Paschke S, Thomas J, Wolff M, Neef M et al. Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: evidence for a receptor-specific mechanism. Hepatology 2001;34 (5):884-8.
13. Islam MZ, Williams BC, Madhavan K.K, Hayes PC, Hadoke PW. Selective alteration of agonist-mediated contraction in hepatic arteries isolated from patients with cirrhosis. Gastroenterology 2000;118 (4):765-71.
14. Helmy A, Jalan R, Newby DE, Johnston NR, Hayes PC, Webb DJ. Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology 2001;33 (4):826-31.
15. Sitzmann JV, Wu Y, Aguilera G, Cahill PA, Burns RC. Loss of angiotensin-II receptors in portal hypertensive rabbits. Hepatology 1995;22 (2):559-64.
16. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60 (8):646-9.
17. Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucl Acids Res 1984;12 (1 Part 1):387-95.
18. Senger M, Flores T, Glatting K, Ernst P, Hotz-Wagenblatt A, Suhai S. W2H:WWW interface to the GCG sequence analysis package. Bioinformatics 1998;14 (5):452-7.
19. Hirasawa A, Shibata K, Horie K, Takei Y, Obika K, Tanaka T et al. Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants. FEBS Lett 1995;363 (3):256-60.
20. Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D'Amico EB, El-Moalem H et al. Subtype specific regulation of human vascular {alpha}1-adrenergic receptors by vessel bed and age. Circulation 1999;100 (23):2336-43.
21. Michielsen PP, Boeckxstaens GE, Sys SU, Herman AG, Pelckmans PA. Role of nitric oxide in hyporeactivity to noradrenaline of isolated aortic rings in portal hypertensive rats. Eur J Pharmacol 1995;273 (1-2):167-74.
22. Hadoke PW, Hayes PC. In vitro evidence for vascular hyporesponsiveness in clinical and experimental cirrhosis. Pharmacol Ther 1997;75 (I):51-68.
23. Bennett WM, Keeffe E, Melnyk C, Mahler D, Rosch J, Porter GA. Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 1975;135 (7):964-71.
24. Pateron D, Oberti F, Lefilliatre P, Veal N, Tazi KA, Sogni P et al. Relationship between vascular reactivity in vitro and blood flows in rats with cirrhosis. Clin Sci (Lond) 1999;97 (3):313-8.
25. Huang YT, Chang SP, Lin HC, Yang MC, Hong CY. Inositol phosphate responses in portal veins from portal hypertensive rats. receptor- and nonreceptor-mediated responses. J Hepatol 1997;26 (2):376-81.
26. Carey RM, Jin XH, Siragy HM. Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens 2001;14 (6 Part 2):98S-102S.
27. Tagawa T, Imaizumi T, Shiramoto M, Endo T, Hironaga K, Takeshita A. V2 receptor-mediated vasodilation in healthy humans. J Cardiovasc Pharmacol 1995;25 (3):387-92.
28. Webb ML, Meek TD. Inhibitors of endothelin. Med Res Rev 1997;17 (1):17-67.
29. Grady EF, Bohm SK, Bunnett NW. Turning off the signal: mechanisms that attenuate signaling by G protein-coupled receptors. Am J Physiol 1997;273 (3 Part 1):G586-601.
30. Huang LY, Tholanikunnel BG, Vakalopoulou E, Malbon CC. The M (r) 35 000 beta-adrenergic receptor mRNA-binding protein induced by agonists requires both an AUUUA pentamer and U-rich domains for RNA recognition. J Biol Chem 1993;268 (34):25769-75.
31. Port JD, Huang LY, Malbon CC. Beta-adrenergic agonists that down-regulate receptor mRNA up-regulate a M (r) 35 000 protein (s) that selectively binds to beta-adrenergic receptor mRNAs. J Biol Chem 1992;267 (33):24103-8.
32. Ouali R, Berthelon MC, Begeot M, Saez JM. Angiotensin II receptor subtypes AT1 and AT2 are down-regulated by angiotensin II through AT1 receptor by different mechanisms. Endocrinology 1997;138 (2):725-33.
33. Lassegue B, Alexander R, Nickenig G, Clark M, Murphy T, Griendling K. Angiotensin II down-regulates the vascular smooth muscle AT1 receptor by transcriptional and post-transcriptional mechanisms. evidence for homologous and heterologous regulation. Mol Pharmacol 1995;48 (4):601-9.
34. Cottet-Maire F, Avdonin PV, Roulet E, Buetler TM, Mermod N, Ruegg UT. Upregulation of vasopressin V1A receptor mRNA and protein in vascular smooth muscle cells following cyclosporin A treatment. Br J Pharmacol 2001;132 (4):909-17.
35. Murasawa S, Matsubara H, Kizima K, Maruyama K, Mori Y, Inada M. Glucocorticoids regulate V1a vasopressin receptor expression by increasing mRNA stability in vascular smooth muscle cells. Hypertension 1995;26 (4):665-9.
36. Hunyady L, Catt KJ, Clark AJ, Gaborik Z. Mechanisms and functions of AT (1) angiotensin receptor internalization. Regul Pept 2000;91 (1-3):29-44.
37. Thomas WG. Regulation of angiotensin II type 1 (AT1) receptor function. Regul Pept 1999;79 (1):9-23.
38. Modrall JG, Nanamori M, Sadoshima J, Barnhart DC, Stanley JC, Neubig RR. ANG II type 1 receptor downregulation does not require receptor endocytosis or G protein coupling. Am J Physiol Cell Physiol 2001;281 (3):C801-9.